MILLENNIUM PHARMACEUTICALS, INC.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1993-01-01
- Employees
- 1K
- Market Cap
- -
Dose Escalation Study of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid Malignancies
- Conditions
- Interventions
- First Posted Date
- 2011-05-10
- Last Posted Date
- 2019-08-08
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 68
- Registration Number
- NCT01351350
Study of Oral Ixazomib in Combination With Melphalan and Prednisone in Participants With Newly Diagnosed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2011-04-14
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 61
- Registration Number
- NCT01335685
Study of Oral Ixazomib in Adult Participants With Relapsed or Refractory Light Chain Amyloidosis
- First Posted Date
- 2011-03-21
- Last Posted Date
- 2020-04-01
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT01318902
- Locations
- 🇩🇪
Universitatsklinikum Heidelberg Innere Medizin V; Hamatologie, Onkologie und Rheumatologie, Heidelberg, Germany
🇺🇸Mount Sinai Medical Center, New York, New York, United States
🇮🇹Amyloidosis Research & Treatment Center, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
- First Posted Date
- 2010-10-19
- Last Posted Date
- 2014-07-21
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 416
- Registration Number
- NCT01224171
- Locations
- 🇺🇸
Atlanta Gastroenterology Associates, Atlanta, Georgia, United States
🇺🇸University of Kentucky Medical Center, Lexington, Kentucky, United States
🇺🇸Gastroenterology of the Rockies, Lafayette, Colorado, United States
A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2010-10-08
- Last Posted Date
- 2018-03-14
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 65
- Registration Number
- NCT01217957
- Locations
- 🇺🇸
Mayo Clinic Jacksonville, Jacksonville, Florida, United States
🇺🇸Mt Sinai Medical Center, Miami Beach, Florida, United States
🇺🇸Mayo Clinic Arizona, Scottsdale, Arizona, United States
A Study of TAK-441 in Adult Patients With Advanced Nonhematologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2010-09-17
- Last Posted Date
- 2013-07-02
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 34
- Registration Number
- NCT01204073
- Locations
- 🇺🇸
Mayo Clinic, Scottsdale, Arizona, United States
🇺🇸Premiere Oncology, A Medical Corporation, Santa Monica, California, United States
Study of the Safety and Efficacy of MLN1202 in Patients in Multiple Sclerosis
- First Posted Date
- 2010-09-13
- Last Posted Date
- 2010-09-13
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT01199640
Surveillance Study of Patients With Newly Diagnosed Osteosarcoma
- First Posted Date
- 2010-09-02
- Last Posted Date
- 2017-01-19
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT01194284
- Locations
- 🇦🇹
AKH Wien Universitätsklinik für Innere Medizin I Klinische Abteilung für Onkologie, Wien, Austria
Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
- First Posted Date
- 2010-09-01
- Last Posted Date
- 2017-05-17
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 1560
- Registration Number
- NCT01193244
Study Comparing Orteronel Plus Prednisone in Participants With Metastatic Castration-Resistant Prostate Cancer.
- Conditions
- Interventions
- First Posted Date
- 2010-09-01
- Last Posted Date
- 2018-12-19
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 1099
- Registration Number
- NCT01193257